ZA200108012B - Method of enhancing the efficacy of anti-tumor agents. - Google Patents

Method of enhancing the efficacy of anti-tumor agents.

Info

Publication number
ZA200108012B
ZA200108012B ZA200108012A ZA200108012A ZA200108012B ZA 200108012 B ZA200108012 B ZA 200108012B ZA 200108012 A ZA200108012 A ZA 200108012A ZA 200108012 A ZA200108012 A ZA 200108012A ZA 200108012 B ZA200108012 B ZA 200108012B
Authority
ZA
South Africa
Prior art keywords
efficacy
enhancing
tumor agents
tumor
agents
Prior art date
Application number
ZA200108012A
Other languages
English (en)
Inventor
M Steven Piver
David F Silver
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of ZA200108012B publication Critical patent/ZA200108012B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
ZA200108012A 1999-04-27 2001-09-28 Method of enhancing the efficacy of anti-tumor agents. ZA200108012B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents

Publications (1)

Publication Number Publication Date
ZA200108012B true ZA200108012B (en) 2003-03-26

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108012A ZA200108012B (en) 1999-04-27 2001-09-28 Method of enhancing the efficacy of anti-tumor agents.

Country Status (18)

Country Link
US (3) US6171620B1 (https=)
EP (1) EP1212068A4 (https=)
JP (1) JP2002542296A (https=)
KR (1) KR100693796B1 (https=)
CN (1) CN1188137C (https=)
AU (1) AU781301B2 (https=)
BG (1) BG64940B1 (https=)
BR (1) BR0010082A (https=)
CA (1) CA2368618C (https=)
HU (1) HUP0200840A3 (https=)
IL (1) IL146012A0 (https=)
MX (1) MXPA01010899A (https=)
NO (1) NO20015227L (https=)
NZ (1) NZ514521A (https=)
PL (1) PL350918A1 (https=)
RU (1) RU2271829C2 (https=)
WO (1) WO2000064455A1 (https=)
ZA (1) ZA200108012B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531179A (ja) 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
WO2019083023A1 (ja) * 2017-10-26 2019-05-02 国立大学法人筑波大学 癌の治療に使用するための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
BG64940B1 (bg) 2006-10-31
US6426094B2 (en) 2002-07-30
BR0010082A (pt) 2002-01-15
HUP0200840A2 (hu) 2002-07-29
WO2000064455A1 (en) 2000-11-02
PL350918A1 (en) 2003-02-10
JP2002542296A (ja) 2002-12-10
EP1212068A4 (en) 2007-03-14
US6620779B2 (en) 2003-09-16
NO20015227D0 (no) 2001-10-25
CA2368618A1 (en) 2000-11-02
CA2368618C (en) 2011-03-01
KR20020000557A (ko) 2002-01-05
CN1352561A (zh) 2002-06-05
NZ514521A (en) 2003-07-25
BG106057A (en) 2002-04-30
HUP0200840A3 (en) 2003-04-28
US20010000730A1 (en) 2001-05-03
AU781301B2 (en) 2005-05-12
RU2271829C2 (ru) 2006-03-20
NO20015227L (no) 2001-12-27
MXPA01010899A (es) 2003-06-24
KR100693796B1 (ko) 2007-03-12
EP1212068A1 (en) 2002-06-12
AU4486300A (en) 2000-11-10
US6171620B1 (en) 2001-01-09
US20020198153A1 (en) 2002-12-26
IL146012A0 (en) 2002-07-25
CN1188137C (zh) 2005-02-09

Similar Documents

Publication Publication Date Title
ZA200108012B (en) Method of enhancing the efficacy of anti-tumor agents.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
GB9903830D0 (en) Process-systems integration method
ZA200200477B (en) 2-pyrazolin-5-ones.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
ZA200202537B (en) Pour-on-formulations.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
MXPA01010700A (es) Acabado ferrofluidico.
IL144120A0 (en) Defibrillator system
ZA200105690B (en) Novel treatment.
ZA200202486B (en) Set defence means.
ZA200002020B (en) Prospecting technique.
GB9905817D0 (en) Methods
ZA200110046B (en) Therapeutic agents.
ZA200204581B (en) Nitro-sulfobenzamides.
ZA200109120B (en) Use of Arylalkanoylpyridazines.
ZA200108129B (en) Histidine protein-phosphatase.
GB9914943D0 (en) Methods
GB9908525D0 (en) Methods
GB9906382D0 (en) The ropeclean retainer
ZA200204584B (en) Therapeutic agents.
ZA99132B (en) Therapeutic agents.
GB9929768D0 (en) P.e.c.s.
GB9929289D0 (en) Retainer
AU140511S (en) Retainer